XLO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

Stats
Today's Volume	229 361
Average Volume	1.24M
Market Cap	43.56M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.300 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.420
ATR14	$0.0160 (1.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Luptakova Katarina	Buy	59 333	Stock Option (right to buy)
2024-05-01	Brennan Kevin M.	Buy	20 000	Stock Option (right to buy)
2024-05-01	Frankenfield Christopher James	Buy	208 000	Stock Option (right to buy)
2024-05-01	Russo Rene	Buy	474 000	Stock Option (right to buy)
2024-04-02	Gilead Sciences, Inc.	Buy	485 250	Common Stock

INSIDER POWER
92.68
Last 95 transactions
Buy: 17 386 240 \| Sell: 51 387 838

Volume Correlation

Long: -0.19 (neutral)

Short: -0.86 (strong negative)

Signal:(50.292) Neutral

Xilio Therapeutics, Inc. Correlation

10 Most Positive Correlations
XFOR	0.899
DSGN	0.894
PFSW	0.888
IDN	0.888
CTIC	0.879
CRON	0.877
CDXC	0.876
AMRB	0.872
NWLI	0.87
MU	0.866

10 Most Negative Correlations
LIAN	-0.832
SBNYP	-0.819
TUEM	-0.819
STAB	-0.818
LUNA	-0.817
ATAK	-0.813
CFV	-0.812
BTTX	-0.806
AHPI	-0.802
ISPC	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xilio Therapeutics, Inc. Correlation - Currency/Commodity

-0.73
( moderate negative )

-0.65
( moderate negative )

0.00
( neutral )

-0.58
( weak negative )

-0.28
( neutral )

Xilio Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2023
Revenue:	$0
Gross Profit:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2022
Revenue:	$0
Gross Profit:	$-1.85M (0.00 %)
EPS:	$-3.19

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-13.52

Financial Reports:

No articles found.

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Realtime updates for Xilio Therapeutics, Inc. [XLO]

Upcoming Earnings Alert